Therapeutic trial of a pyrazole derivative, KB-95, for patients with rheumatoid arthritis.
A phenylbutazone-like pyrazole derivative, Sandoz KB-95, claimed to have antiserotonin, anti-inflammatory and analgesic properties, was tested on patients with rheumatoid arthritis. A double-blind study on 17 patients with definite or classical rheumatoid arthritis was performed for two-week periods on both KB-95 and placebo. Grip strength, the time to walk 50 feet, the number of other analgesic tablets taken daily, the erythrocyte sedimentation rate and a subjective rating of pain were the parameters of measurement. KB-95 failed to produce significantly more improvement than the placebo in this trial and was therefore considered not to be a useful drug for the treatment of rheumatoid arthritis. No acute toxic effects were observed to this dose of 300 mg. given three times daily.
D000893:Anti-Inflammatory Agents; D001172:Arthritis, Rheumatoid; D001799:Blood Sedimentation; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D010146:Pain; D010653:Phenylbutazone; D011720:Pyrazoles; D013607:Tablets
D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; D013607:Tablets; C031280:pyrazole; D010653:Phenylbutazone
ARTHRITIS, RHEUMATOID; PYRAZOLES